Soligenix Boosts At-The-Market Offering Capacity by $2.956M
SNGX has more than doubled off its 52-week low of $0.28 on elevated volume (3.2× avg).
Summary
Soligenix has increased its at-the-market (ATM) share offering capacity by an additional $2.956 million. This follows the company's Q1 report on May 8th, which confirmed a going concern warning, zero revenue, and detailed prior highly dilutive ATM sales. The company also recently halted its pivotal Phase 3 FLASH2 trial for futility in April. This additional capacity, representing over 20% of the current market cap, signals continued reliance on dilutive equity financing to sustain operations.
At the time of this announcement, SNGX was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $0.28 to $6.23. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.